You are here: Industry Insights > Gilead Sciences

News List

Gilead Sciences, Galapagos enter into deal worth $5B biospectrumasia
July 15, 2019
Galapagos will receive a $3.95 billion upfront payment and a $1.1 billion equity investment from Gilead.
Gilead Sciences announces launch of Asia Pacific Rainbow Grant 2019 biospectrumasia
July 04, 2019
Grant program invites applications from HIV-Focused Community-Based organizations in the Asia Pacific region
Gilead Sciences announces launch of Asia Pacific Rainbow Grants Program in India expresspharma
July 04, 2019
This year’s grants program seeks to improve the quality of life of people living with HIV by focusing on three priority areas
Phase 3 STELLAR-4 Study of Selonsertib Did Not Meet Primary Endpoint americanpharmaceuticalreview
February 13, 2019
Gilead Sciences announced STELLAR-4, a Phase 3, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of selonsertib, an investigational, once-daily, oral inhibitor of apoptosis signal-regulating kinase 1 (ASK1).....
PhRMA Welcomes Genentech and Gilead Sciences to Association americanpharmaceuticalreview
January 21, 2019
The Pharmaceutical Research and Manufacturers of America (PhRMA) announced Genentech, a member of the Roche Group, and Gilead Sciences have joined the association as members....
Gilead and Agenus sign cancer drug development deal pharmaceutical-technology
January 03, 2019
Gilead Sciences has partnered with US-based biotechnology company Agenus for the development and commercialisation of up to five immuno-oncology (I-O) treatments.
Gilead inks $1.8 bn deal with immuno-oncology biotech Agenus pharmafile
December 24, 2018
California-based firm Gilead Sciences and Massachusetts-based immuno-oncology biotech Agenus have announced that they have entered into a partnership focused on the development
Gilead appoints current Roche Pharmaceuticals CEO as new CEO and chairman pharmaceutical-technology
December 11, 2018
The board of directors at Gilead Sciences has announced it has chosen Daniel O’Day, the current CEO of Roche Pharmaceuticals and member of the Roche Group’s corporate executive committee.....
Gilead, looking for cancer sales, swipes Roche pharma chief Daniel O'Day for CEO post fiercepharma
December 11, 2018
With Gilead’s CEO on the way out and revenues tumbling, the company needs a leader who can pump up cancer sales. And it may have found just that in the ranks of the world's biggest cancer drug maker.
England's cost watchdogs nix Novartis' Kymriah for adults fiercepharma
September 30, 2018
Cost watchdogs in England turned away Kymriah in adults with relapsed or refractory diffuse large B-cell lymphoma after two prior therapies.

Previous page 1 2 3 4 5 Next page